{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:22:09Z","timestamp":1793924529047,"version":"4.8.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00038\/5"],"award-info":[{"award-number":["MC_UU_00038\/5"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CDF C57404\/A21782"],"award-info":[{"award-number":["CDF C57404\/A21782"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["Stg no. IDRE-715127"],"award-info":[{"award-number":["Stg no. IDRE-715127"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Multiple studies have demonstrated that cancer cells with microsatellite instability (MSI) are intolerant to loss of the Werner syndrome helicase (WRN), whereas microsatellite-stable (MSS) cancer cells are not. Therefore, WRN represents a promising new synthetic lethal target for developing drugs to treat cancers with MSI. Given the uncertainty of how effective inhibitors of WRN activity will prove in clinical trials, and the likelihood of tumours developing resistance to WRN inhibitors, alternative strategies for impeding WRN function are needed. Proteolysis-targeting chimeras (PROTACs) are heterobifunctional small molecules that target specific proteins for degradation. Here, we engineered the\n                    <jats:italic>WRN<\/jats:italic>\n                    locus so that the gene product is fused to a bromodomain (Bd)-tag, enabling conditional WRN degradation with the AGB-1 PROTAC specific for the Bd-tag. Our data revealed that WRN degradation is highly toxic in MSI but not MSS cell lines. In MSI cells, WRN degradation caused G\n                    <jats:sub>2<\/jats:sub>\n                    \/M arrest, chromosome breakage and ATM kinase activation. We also describe a multi-colour cell-based platform for facile testing of selective toxicity in MSI versus MSS cell lines. Together, our data show that a degrader approach is a potentially powerful way of targeting WRN in MSI cancers and paves the way for the development of WRN-specific PROTAC compounds.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-71160-5","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T07:02:18Z","timestamp":1725606138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["PROTAC-mediated conditional degradation of the WRN helicase as a potential strategy for selective killing of cancer cells with microsatellite instability"],"prefix":"10.1038","volume":"14","author":[{"given":"Vikram","family":"Tejwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Macartney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Bandau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Alabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Saredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"71160_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/emboj.2008.15","volume":"27","author":"R Hakem","year":"2008","unstructured":"Hakem, R. DNA-damage repair; the good, the bad, and the ugly. EMBO J. 27, 589\u2013605 (2008).","journal-title":"EMBO J."},{"key":"71160_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrm1907","volume":"7","author":"J Jiricny","year":"2006","unstructured":"Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 7, 335\u2013346 (2006).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"71160_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012633","volume":"5","author":"J Jiricny","year":"2013","unstructured":"Jiricny, J. Postreplicative mismatch repair. Cold Spring Harb. Perspect. Biol. 5, a012633. https:\/\/doi.org\/10.1101\/cshperspect.a012633 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"71160_CR4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/diagnostics11030544","volume":"11","author":"FYF Tieng","year":"2021","unstructured":"Tieng, F. Y. F., Abu, N., Lee, L.-H. & Ab Mutalib, N.-S. Microsatellite instability in colorectal cancer liquid biopsy\u2014current updates on its potential in non-invasive detection, prognosis and as a predictive marker. Diagnostics 11, 544 (2021).","journal-title":"Diagnostics"},{"key":"71160_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/cr.2007.115","volume":"18","author":"G-M Li","year":"2008","unstructured":"Li, G.-M. Mechanisms and functions of DNA mismatch repair. Cell Res. 18, 85\u201398 (2008).","journal-title":"Cell Res."},{"key":"71160_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/s0959-8049(99)00045-3","volume":"35","author":"M Nilbert","year":"1999","unstructured":"Nilbert, M., Planck, M., Fernebro, E., Borg, A. & Johnson, A. Microsatellite instability is rare in rectal carcinomas and signifies hereditary cancer. Eur. J. Cancer 35, 942\u2013945. https:\/\/doi.org\/10.1016\/s0959-8049(99)00045-3 (1999).","journal-title":"Eur. J. Cancer"},{"key":"71160_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/qjmed\/hcv137","volume":"109","author":"AK Tiwari","year":"2016","unstructured":"Tiwari, A. K., Roy, H. K. & Lynch, H. T. Lynch syndrome in the 21st century: clinical perspectives. QJM 109, 151\u2013158 (2016).","journal-title":"QJM"},{"key":"71160_CR8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/gcc.23015","volume":"61","author":"MC Olave","year":"2022","unstructured":"Olave, M. C. & Graham, R. P. Mismatch repair deficiency: The what, how and why it is important. Genes Chromosom. Cancer 61, 314\u2013321 (2022).","journal-title":"Genes Chromosom. Cancer"},{"key":"71160_CR9","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/nm.4191","volume":"22","author":"RJ Hause","year":"2016","unstructured":"Hause, R. J., Pritchard, C. C., Shendure, J. & Salipante, S. J. Classification and characterization of microsatellite instability across 18 cancer types. Nat. Med. 22, 1342\u20131350 (2016).","journal-title":"Nat. Med."},{"key":"71160_CR10","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.1038\/onc.2008.217","volume":"27","author":"L Laghi","year":"2008","unstructured":"Laghi, L., Bianchi, P. & Malesci, A. Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene 27, 6313\u20136321 (2008).","journal-title":"Oncogene"},{"key":"71160_CR11","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","volume":"138","author":"CR Boland","year":"2010","unstructured":"Boland, C. R. & Goel, A. Microsatellite instability in colorectal cancer. Gastroenterology 138, 2073-2087.e3 (2010).","journal-title":"Gastroenterology"},{"key":"71160_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s004280000325","volume":"438","author":"AM Chiaravalli","year":"2001","unstructured":"Chiaravalli, A. M. et al. Immunohistochemical pattern of hMSH2\/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Archiv 438, 39\u201348 (2001).","journal-title":"Virchows Archiv"},{"key":"71160_CR13","unstructured":"World Cancer Research Fund International. Stomach Cancer Statistics, https:\/\/www.wcrf.org\/cancer-trends\/stomach-cancer-statistics\/ (2022). Accessed 22 May 2024."},{"key":"71160_CR14","unstructured":"International Agency for Research on Cancer (WHO). Global Cancer Observatory, https:\/\/gco.iarc.fr\/en (2024). Accessed 22 May 2024."},{"key":"71160_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41586-019-1102-x","volume":"568","author":"EM Chan","year":"2019","unstructured":"Chan, E. M. et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 568, 551\u2013556 (2019).","journal-title":"Nature"},{"key":"71160_CR16","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.43333","volume":"8","author":"S Lieb","year":"2019","unstructured":"Lieb, S. et al. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. Elife 8, e43333 (2019).","journal-title":"Elife"},{"key":"71160_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"71160_CR18","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"71160_CR19","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773\u2013779 (2018).","journal-title":"J. Clin. Oncol."},{"key":"71160_CR20","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182\u20131191 (2017).","journal-title":"Lancet Oncol."},{"key":"71160_CR21","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1158\/2326-6066.CIR-18-0683","volume":"7","author":"C Gurjao","year":"2019","unstructured":"Gurjao, C. et al. Intrinsic resistance to immune checkpoint blockade in a mismatch repair\u2013deficient colorectal cancer. Cancer Immunol. Res. 7, 1230\u20131236 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"71160_CR22","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1158\/1078-0432.CCR-20-4632","volume":"27","author":"AM Monjazeb","year":"2021","unstructured":"Monjazeb, A. M. et al. A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer. Clin. Cancer Res. 27, 2470\u20132480 (2021).","journal-title":"Clin. Cancer Res."},{"key":"71160_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR\u2013Cas9 screens. Nature 568, 511\u2013516 (2019).","journal-title":"Nature"},{"key":"71160_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.isci.2019.02.006","volume":"13","author":"L Kategaya","year":"2019","unstructured":"Kategaya, L., Perumal, S. K., Hager, J. H. & Belmont, L. D. Werner syndrome helicase is required for the survival of cancer cells with microsatellite instability. Iscience 13, 488\u2013497 (2019).","journal-title":"Iscience"},{"key":"71160_CR25","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022111998","volume":"42","author":"V Mengoli","year":"2023","unstructured":"Mengoli, V. et al. WRN helicase and mismatch repair complexes independently and synergistically disrupt cruciform DNA structures. EMBO J. 42, e111998 (2023).","journal-title":"EMBO J."},{"key":"71160_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41586-020-2769-8","volume":"586","author":"N van Wietmarschen","year":"2020","unstructured":"van Wietmarschen, N. et al. Repeat expansions confer WRN dependence in microsatellite-unstable cancers. Nature 586, 292\u2013298 (2020).","journal-title":"Nature"},{"key":"71160_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.gde.2021.06.014","volume":"71","author":"N van Wietmarschen","year":"2021","unstructured":"van Wietmarschen, N., Nathan, W. J. & Nussenzweig, A. The WRN helicase: Resolving a new target in microsatellite unstable cancers. Curr. Opin. Genet. Dev. 71, 34\u201338 (2021).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"71160_CR28","doi-asserted-by":"publisher","first-page":"6059","DOI":"10.1038\/s41467-024-50178-3","volume":"15","author":"F Rodr\u00edguez P\u00e9rez","year":"2024","unstructured":"Rodr\u00edguez P\u00e9rez, F. et al. WRN inhibition leads to its chromatin-associated degradation via the PIAS4-RNF4-p97\/VCP axis. Nat. Commun. 15, 6059 (2024).","journal-title":"Nat. Commun."},{"key":"71160_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev-biochem-060713-035428","volume":"83","author":"DL Croteau","year":"2014","unstructured":"Croteau, D. L., Popuri, V., Opresko, P. L. & Bohr, V. A. Human RecQ helicases in DNA repair, recombination, and replication. Annu. Rev. Biochem. 83, 519 (2014).","journal-title":"Annu. Rev. Biochem."},{"key":"71160_CR30","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1021\/acs.biochem.2c00599","volume":"62","author":"MJ Parker","year":"2023","unstructured":"Parker, M. J. et al. Identification of 2-sulfonyl\/sulfonamide pyrimidines as covalent inhibitors of WRN using a multiplexed high-throughput screening assay. Biochemistry 62, 2147\u20132160 (2023).","journal-title":"Biochemistry"},{"key":"71160_CR31","doi-asserted-by":"publisher","first-page":"e202300613","DOI":"10.1002\/cmdc.202300613","volume":"19","author":"A Heuser","year":"2024","unstructured":"Heuser, A. et al. Challenges for the discovery of non-covalent WRN helicase inhibitors. ChemMedChem 19, e202300613 (2024).","journal-title":"ChemMedChem"},{"key":"71160_CR32","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1073\/pnas.1006423108","volume":"108","author":"M Aggarwal","year":"2011","unstructured":"Aggarwal, M., Sommers, J. A., Shoemaker, R. H. & Brosh, R. M. Jr. Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc. Natl. Acad. Sci. 108, 1525\u20131530 (2011).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"71160_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.chembiol.2012.10.016","volume":"20","author":"GH Nguyen","year":"2013","unstructured":"Nguyen, G. H. et al. A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. Chem. Biol. 20, 55\u201362 (2013).","journal-title":"Chem. Biol."},{"key":"71160_CR34","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1158\/0008-5472.CAN-12-2975","volume":"73","author":"M Aggarwal","year":"2013","unstructured":"Aggarwal, M. et al. Werner syndrome helicase has a critical role in DNA damage responses in the absence of a functional fanconi anemia pathway. Cancer Res. 73, 5497\u20135507 (2013).","journal-title":"Cancer Res."},{"key":"71160_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210525","volume":"14","author":"JA Sommers","year":"2019","unstructured":"Sommers, J. A. et al. A high-throughput screen to identify novel small molecule inhibitors of the Werner Syndrome Helicase-Nuclease (WRN). PLoS ONE 14, e0210525 (2019).","journal-title":"PLoS ONE"},{"key":"71160_CR36","first-page":"B20","volume":"23","author":"G Picco","year":"2024","unstructured":"Picco, G. et al. Novel WRN helicase inhibitors selectively target microsatellite unstable cancer cells. Cancer Discov. 23, B20 (2024).","journal-title":"Cancer Discov."},{"key":"71160_CR37","doi-asserted-by":"publisher","first-page":"ND11","DOI":"10.1158\/1538-7445.AM2024-ND11","volume":"84","author":"S Kikuchi","year":"2024","unstructured":"Kikuchi, S. et al. Abstract ND11: Chemoproteomic-enabled discovery of VVD-214, a synthetic lethal allosteric inhibitor of WRN helicase. Cancer Res. 84, ND11 (2024).","journal-title":"Cancer Res."},{"key":"71160_CR38","doi-asserted-by":"publisher","first-page":"PR007","DOI":"10.1158\/1535-7163.TARG-23-PR007","volume":"22","author":"M Cortes-Cros","year":"2023","unstructured":"Cortes-Cros, M. et al. Abstract PR007: Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability. Mol. Cancer Therap. 22, PR007 (2023).","journal-title":"Mol. Cancer Therap."},{"key":"71160_CR39","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA 98, 8554\u20138559. https:\/\/doi.org\/10.1073\/pnas.141230798 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71160_CR40","unstructured":"Biopharma PEG. PROTACs VS. Traditional Small Molecule Inhibitors, https:\/\/www.biochempeg.com\/article\/233.html (2021). Accessed 22 May 2024."},{"key":"71160_CR41","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","volume":"4","author":"X Sun","year":"2019","unstructured":"Sun, X. et al. PROTACs: Great opportunities for academia and industry. Signal Transduct. Target Ther. 4, 64. https:\/\/doi.org\/10.1038\/s41392-019-0101-6 (2019).","journal-title":"Signal Transduct. Target Ther."},{"key":"71160_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: The past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200. https:\/\/doi.org\/10.1038\/s41573-021-00371-6 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"71160_CR43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","volume":"11","author":"H Gao","year":"2020","unstructured":"Gao, H., Sun, X. & Rao, Y. PROTAC technology: Opportunities and challenges. ACS Med. Chem. Lett. 11, 237\u2013240 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"71160_CR44","doi-asserted-by":"publisher","first-page":"15477","DOI":"10.1021\/acs.jmedchem.1c01532","volume":"64","author":"AG Bond","year":"2021","unstructured":"Bond, A. G. et al. Development of BromoTag: A \u201cBump-and-Hole\u201d\u2013PROTAC system to induce potent, rapid, and selective degradation of tagged target proteins. J. Med. Chem. 64, 15477\u201315502 (2021).","journal-title":"J. Med. Chem."},{"key":"71160_CR45","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","volume":"154","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380\u20131389. https:\/\/doi.org\/10.1016\/j.cell.2013.08.021 (2013).","journal-title":"Cell"},{"key":"71160_CR46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nmeth.2857","volume":"11","author":"B Shen","year":"2014","unstructured":"Shen, B. et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat. Methods 11, 399\u2013402. https:\/\/doi.org\/10.1038\/nmeth.2857 (2014).","journal-title":"Nat. Methods"},{"key":"71160_CR47","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1006\/bbrc.2000.2576","volume":"270","author":"M Morimoto","year":"2000","unstructured":"Morimoto, M., Nishida, T., Honda, R. & Yasuda, H. Modification of cullin-1 by ubiquitin-like protein Nedd8 enhances the activity of SCF(skp2) toward p27(kip1). Biochem. Biophys. Res. Commun. 270, 1093\u20131096. https:\/\/doi.org\/10.1006\/bbrc.2000.2576 (2000).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"71160_CR48","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41586-020-2000-y","volume":"578","author":"K Baek","year":"2020","unstructured":"Baek, K. et al. NEDD8 nucleates a multivalent cullin-RING-UBE2D ubiquitin ligation assembly. Nature 578, 461\u2013466. https:\/\/doi.org\/10.1038\/s41586-020-2000-y (2020).","journal-title":"Nature"},{"key":"71160_CR49","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1083\/jcb.151.7.1381","volume":"151","author":"LB Schultz","year":"2000","unstructured":"Schultz, L. B., Chehab, N. H., Malikzay, A. & Halazonetis, T. D. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J. Cell Biol. 151, 1381\u20131390 (2000).","journal-title":"J. Cell Biol."},{"key":"71160_CR50","doi-asserted-by":"publisher","first-page":"42462","DOI":"10.1074\/jbc.C100466200","volume":"276","author":"S Burma","year":"2001","unstructured":"Burma, S., Chen, B. P., Murphy, M., Kurimasa, A. & Chen, D. J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 276, 42462\u201342467 (2001).","journal-title":"J. Biol. Chem."},{"key":"71160_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","volume":"108","author":"J Smith","year":"2010","unstructured":"Smith, J., Tho, L. M., Xu, N. & Gillespie, D. A. The ATM\u2013Chk2 and ATR\u2013Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 108, 73\u2013112 (2010).","journal-title":"Adv. Cancer Res."},{"key":"71160_CR52","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/ncb2201","volume":"13","author":"C Lukas","year":"2011","unstructured":"Lukas, C. et al. 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat. Cell Biol. 13, 243\u2013253 (2011).","journal-title":"Nat. Cell Biol."},{"key":"71160_CR53","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/gerona\/60.6.695","volume":"60","author":"A Mocali","year":"2005","unstructured":"Mocali, A., Giovannelli, L., Dolara, P. & Paoletti, F. The comet assay approach to senescent human diploid fibroblasts identifies different phenotypes and clarifies relationships among nuclear size, DNA content, and DNA damage. J. Gerontol. Ser. A: Biol. Sci. Med. Sci. 60, 695\u2013701 (2005).","journal-title":"J. Gerontol. Ser. A: Biol. Sci. Med. Sci."},{"key":"71160_CR54","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/nar\/gkaa1202","volume":"49","author":"\u00c1 Dos Santos","year":"2021","unstructured":"Dos Santos, \u00c1. et al. DNA damage alters nuclear mechanics through chromatin reorganization. Nucleic Acids Res. 49, 340\u2013353 (2021).","journal-title":"Nucleic Acids Res."},{"key":"71160_CR55","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/1535-7163.MCT-21-0934","volume":"21","author":"A Zimmermann","year":"2022","unstructured":"Zimmermann, A. et al. A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies. Mol. Cancer Therap. 21, 859\u2013870 (2022).","journal-title":"Mol. Cancer Therap."},{"key":"71160_CR56","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1101\/gad.1200304","volume":"18","author":"R Kitagawa","year":"2004","unstructured":"Kitagawa, R., Bakkenist, C. J., McKinnon, P. J. & Kastan, M. B. Phosphorylation of SMC1 is a critical downstream event in the ATM\u2013NBS1\u2013BRCA1 pathway. Genes Dev. 18, 1423\u20131438 (2004).","journal-title":"Genes Dev."},{"key":"71160_CR57","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.cell.2007.03.009","volume":"129","author":"A Smogorzewska","year":"2007","unstructured":"Smogorzewska, A. et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 129, 289\u2013301. https:\/\/doi.org\/10.1016\/j.cell.2007.03.009 (2007).","journal-title":"Cell"},{"key":"71160_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-024-07350-y","volume":"629","author":"S Ferretti","year":"2024","unstructured":"Ferretti, S. et al. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers. Nature 629, 1\u20137 (2024).","journal-title":"Nature"},{"key":"71160_CR59","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1101\/gad.351085.123","volume":"37","author":"D Zong","year":"2023","unstructured":"Zong, D. et al. Comprehensive mapping of cell fates in microsatellite unstable cancer cells supports dual targeting of WRN and ATR. Genes Dev. 37, 913\u2013928 (2023).","journal-title":"Genes Dev."},{"key":"71160_CR60","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1074\/jbc.M116.768853","volume":"292","author":"N Ohoka","year":"2017","unstructured":"Ohoka, N. et al. In vivo knockdown of pathogenic proteins via specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs). J. Biol. Chem. 292, 4556\u20134570. https:\/\/doi.org\/10.1074\/jbc.M116.768853 (2017).","journal-title":"J. Biol. Chem."},{"key":"71160_CR61","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina, K. et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc. Natl. Acad. Sci. USA 113, 7124\u20137129. https:\/\/doi.org\/10.1073\/pnas.1521738113 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71160_CR62","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1021\/acs.jmedchem.6b01816","volume":"61","author":"B Zhou","year":"2018","unstructured":"Zhou, B. et al. Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J. Med. Chem. 61, 462\u2013481. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01816 (2018).","journal-title":"J. Med. Chem."},{"key":"71160_CR63","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/leu.2016.393","volume":"31","author":"DT Saenz","year":"2017","unstructured":"Saenz, D. T. et al. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia 31, 1951\u20131961. https:\/\/doi.org\/10.1038\/leu.2016.393 (2017).","journal-title":"Leukemia"},{"key":"71160_CR64","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","volume":"25","author":"GM Burslem","year":"2018","unstructured":"Burslem, G. M. et al. The advantages of targeted protein degradation over inhibition: An RTK case study. Cell Chem. Biol. 25, 67-77.e63. https:\/\/doi.org\/10.1016\/j.chembiol.2017.09.009 (2018).","journal-title":"Cell Chem. Biol."},{"key":"71160_CR65","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias, M. P., Moser, S. C., Ganesan, S. & Jonkers, J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 18, 773\u2013791. https:\/\/doi.org\/10.1038\/s41571-021-00532-x (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"71160_CR66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","volume":"560","author":"SM Noordermeer","year":"2018","unstructured":"Noordermeer, S. M. et al. The shieldin complex mediates 53BP1-dependent DNA repair. Nature 560, 117\u2013121 (2018).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71160-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71160-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71160-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T08:10:44Z","timestamp":1725610244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71160-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["71160"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-71160-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20824"}}